Global site reproducibility of characterizing biomarkers in cfTNA from liquid biopsy samples using the targeted Oncomine Precision Assay

High complexity NGS workflows impact the ability to achieve consistent inter-laboratory performance. Often it is highly dependent on operator proficiency and institutional systems designed to minimize variability of testing performance. Here, we describe analytical performance and reproducibility of an automated next-generation sequencing (NGS) pan-cancer DNA & RNA assay at two global laboratory sites located in Durham, NC, USA and Beijing, China. The Oncomine™ Precision Assay on the Genexus™ Integrated Sequencer (OPAGX) is a targeted, NGS assay that detects biomarkers across 50 genes from both solid tissue and liquid biopsy samples. This assay utilizes unique molecular identifiers (UMIs) for error correction in sequencing and improved sensitivity for detection of single nucleotide variants (SNVs), small insertions or deletions, gene fusions, and amplifications in liquid biopsy samples.


Complete the form below to explore the methods, results, and conclusions of this study.